Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

PURPOSE To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes. PATIENTS AND METHODS In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first site-specific recurrence was evaluated by using cumulative incidence and competing risks regression analysis. RESULTS Median follow-up was 12.5 years. The 10-year BCFI was higher for patients with LA-like (86%) BC compared with LB-like (76%), HER2 (73%), and TN (71%; P < .001) BC. TN and HER2 cohorts had higher hazard of BCFI event in the first 4 years after diagnosis (pre-trastuzumab). LB-like cohorts had a continuously higher hazard of BCFI event over time compared with LA-like cohorts. Ten-year overall survival was higher for LA-like (89%) compared with LB-like (83%), HER2 (77%), and TN (75%; P < .001) BC. LB-like subtypes had higher rates of bone as first recurrence site than other subtypes (P = .005). Visceral recurrence as first site was lower for the LA-like subgroup, with similar incidence among the other subgroups when treated with chemotherapy (P = .003). CONCLUSION BC subtypes have different distant recurrence patterns over time. Defining different patterns of BC recurrence can improve BC care through surveillance guidelines and can guide the design of clinical studies.

[1]  I. Henderson,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (Clinical Trial Service Unit (CTSU), Oxford, UK) Lancet 379:432-444, 2012§ , 2013 .

[2]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[3]  R. Gelber,et al.  Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[6]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Gelber,et al.  Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Esteva,et al.  Survival among women with triple receptor-negative breast cancer and brain metastases. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Narod,et al.  Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[12]  R. Gelber,et al.  Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century , 2009, Breast Cancer Research and Treatment.

[13]  A. Giobbie-Hurder,et al.  Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[15]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[16]  M. Fernö,et al.  Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers , 2007, Breast Cancer Research.

[17]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[18]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[20]  Yudi Pawitan,et al.  Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients , 2006, Breast Cancer Research.

[21]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[23]  A. Neugut,et al.  Hormone receptor status and survival in a population‐based cohort of patients with breast carcinoma , 2005, Cancer.

[24]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[25]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Hess,et al.  Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse , 2003, Breast Cancer Research and Treatment.

[27]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Timmerman,et al.  Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Bonetti,et al.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.

[31]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[33]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[34]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[35]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[37]  R. Peto.  EARLY BREAST-CANCER TRIALISTS COLLABORATION , 1987 .

[38]  R. Vihko,et al.  Significance of estrogen and progesterone receptors, disease‐free interval, and site of first metastasis on survival of breast cancer patients , 1985, Cancer.

[39]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[40]  R. Fisher,et al.  The Logic of Inductive Inference , 1935 .